Synmosa Biopharma (ROCO:4114) E10: NT$1.20 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4114 Synmosa Biopharma Corp ROCO:4114
84 GF Score
Price NT$29.80
GF Value NT$33.97
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Synmosa Biopharma E10?

Synmosa Biopharma ROCO:4114 +0.68% 84 E10 is NT$1.20 as of Jun. 2026. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$33.97 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Synmosa Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was NT$0.434. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is NT$1.20 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Synmosa Biopharma's average E10 Growth Rate was 12.10% per year. During the past 3 years, the average E10 Growth Rate was 16.70% per year. During the past 5 years, the average E10 Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Synmosa Biopharma was 36.00% per year. The lowest was 16.70% per year. And the median was 23.10% per year.

As of today (2026-09-04), Synmosa Biopharma's current stock price is NT$29.80. Synmosa Biopharma's E10 for the quarter that ended in Jun. 2026 was NT$1.20. Synmosa Biopharma's Shiller PE Ratio of today is 24.83.

During the past 13 years, the highest Shiller PE Ratio of Synmosa Biopharma was 54.15. The lowest was 24.17. And the median was 34.57.


Synmosa Biopharma  (ROCO:4114) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Synmosa Biopharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=29.80/1.20
=24.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Synmosa Biopharma was 54.15. The lowest was 24.17. And the median was 34.57.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Synmosa Biopharma E10 Related Terms


Synmosa Biopharma E10 Historical Data

* Premium members only.

The historical data trend for Synmosa Biopharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synmosa Biopharma E10 Chart

Synmosa Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.73 0.86 0.98 1.16

Synmosa Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.12 1.16 1.15 1.20

ROCO:4114 vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synmosa Biopharma Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Synmosa Biopharma's Shiller PE Ratio falls into.


ROCO:4114
84GF Score
Synmosa Biopharma Corp ROCO:4114
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synmosa Biopharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Synmosa Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.434/333.9520*333.9520
=0.434

Current CPI (Jun. 2026) = 333.9520.

Synmosa Biopharma Quarterly Data

per share eps CPI Adj_EPS
201609 0.015 241.428 0.021
201612 -0.065 241.432 -0.090
201703 0.002 243.801 0.003
201706 -0.070 244.955 -0.095
201709 0.022 246.819 0.030
201712 0.055 246.524 0.075
201803 0.946 249.554 1.266
201806 0.011 251.989 0.015
201809 0.085 252.439 0.112
201812 0.055 251.233 0.073
201903 0.047 254.202 0.062
201906 -0.018 256.143 -0.023
201909 0.033 256.759 0.043
201912 0.072 256.974 0.094
202003 0.170 258.115 0.220
202006 1.081 257.797 1.400
202009 0.184 260.280 0.236
202012 0.191 260.474 0.245
202103 0.147 264.877 0.185
202106 0.169 271.696 0.208
202109 0.154 274.310 0.187
202112 0.213 278.802 0.255
202203 0.279 287.504 0.324
202206 0.911 296.311 1.027
202209 0.259 296.808 0.291
202212 0.364 296.797 0.410
202303 0.283 301.836 0.313
202306 0.405 305.109 0.443
202309 0.285 307.789 0.309
202312 0.356 306.746 0.388
202403 0.385 312.332 0.412
202406 0.394 314.175 0.419
202409 0.345 315.301 0.365
202412 0.296 315.605 0.313
202503 0.424 319.799 0.443
202506 0.394 322.561 0.408
202509 0.404 324.800 0.415
202512 0.374 324.054 0.385
202603 0.374 330.213 0.378
202606 0.434 333.952 0.434

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of NT$1.20 mean?
Synmosa Biopharma (ROCO:4114) has a E10 of NT$1.20 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Synmosa Biopharma and its competitors.
Is Synmosa Biopharma's E10 too high?
Synmosa Biopharma's current E10 is NT$1.20. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's E10 compare to ZTS?
Synmosa Biopharma's E10 of NT$1.20 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Synmosa Biopharma and its competitors. Synmosa Biopharma's current E10 is NT$1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.97, compared to a current price of NT$29.80 — trading 12.3% below its estimated fair value. The current E10 is NT$1.20. Synmosa Biopharma's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current E10 is NT$1.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?

Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued. The current stock price of NT$29.80 is trading 12.3% below its estimated GF Value™ of NT$33.97. GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.

Key valuation signals for ROCO:4114:

  • E10: NT$1.20
  • GF Value™: NT$33.97 vs. price of NT$29.80 (12.3% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Synmosa Biopharma Business Description

Address No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score

Get the complete analysis for ROCO:4114

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.80
Price
NT$33.97
GF Value